Injectable Drug Delivery Devices Market

The global Injectable Drug Delivery Devices Market is valued at USD 478.9 Billion in 2024 and is projected to reach a value of USD 879.3 Billion by 2035 at a CAGR (Compound Annual Growth Rate) of 5.7% between 2025 and 2035. Market is driven by rising prevalence of autoimmune diseases and advancements in technology that enhance the safety and precision of injectable therapeutics.

Key Highlights

• By Devices, the self-injection devices segment accounted for the highest market share of 61.1% in 2024
• Based on the Therapeutic Application, the hormonal disorders and cancer category accounted for 69.1% of the market share in 2024
• North America dominated the market with 41.1% market share in 2024
• Supportive government policies and healthcare funding initiatives contribute to market growth
• Favourable reimbursement policies and a growing number of blood donors enhance accessibility to these therapeutic solutions and drive demand for apheresis equipment

Major objectives of Injectable Drug Delivery Devices Market Study

• To gain a comprehensive understanding of the Injectable Drug Delivery Devices market by identifying its key segments and subsegments
• To provide an in-depth analysis of the factors driving or hindering market growth, including emerging opportunities and challenges specific to the industry
• To analyze individual market segments for growth trends, future prospects, and their impact on the overall market
• To explore potential opportunities for stakeholders in the Injectable Drug Delivery Devices market and to map out the competitive landscape of leading players
• To profile major companies within the market, evaluating their market share, strengths, and competitive advantages

Devices Overview

​The Devices segment is divided into conventional injection devices and self-injection devices. The self-injection devices segment held the dominant share in 2024, accounting for 61.1% share.

The Apheresis Equipment Market features diverse devices designed for various therapeutic procedures, with significant technological advancements enhancing their safety and efficiency. The dominance of self-injection devices reflects a growing preference for user-friendly and accessible treatment options among patients.​ Apheresis equipment includes systems for therapeutic plasma exchange, red blood cell depletion, plateletpheresis, and leukapheresis, utilizing techniques like centrifugal and membrane-based separations to isolate specific blood components effectively. Innovations such as automated devices and improved monitoring systems are driving the adoption of these technologies in clinical settings, addressing the rising demand for effective treatment of chronic diseases and conditions that require targeted blood component therapy.

Therapeutic Application Overview

The Therapeutic Application segment is separated into autoimmune diseases and hormonal disorders and cancer.

In 2024, the hormonal disorders and cancer segment held a 69.1% share in the Injectable Drug Delivery Devices market. This increase is primarily driven by the growing incidence of cancers, with estimates indicating that approximately 19.3 million new cases were reported globally, highlighting the urgent need for effective treatment options. Additionally, advancements in injectable drug delivery technologies facilitate better management of these conditions, offering efficient and targeted therapies that enhance patient compliance. As patients increasingly prefer convenient administration methods, the combination of comprehensive treatment options for hormonal disorders and innovative cancer therapies further propels the growth of this segment within the market.

Regional Overview

In 2024, the North America, captured 41.1% of the revenue share

The prevalence of chronic diseases, particularly diabetes, is a significant contributing factor projected to affect nearly 8.0% of the population by 2030. Technological advancements, such as self-injection devices and connected systems, play a crucial role in enhancing patient compliance. These innovations have been shown to improve adherence rates by up to 25%. Major players in this region, including Baxter International and Becton Dickinson, are actively engaged in research and development to expand their product offerings and maintain competitive advantages. The robust healthcare infrastructure in the U.S. and Canada furthers the widespread adoption of these devices, facilitating market growth.

Asia Pacific is recognized as the fastest-growing region in the Injectable Drug Delivery Devices Market, influenced by the rising incidence of chronic diseases like diabetes and cancer. Technological advancements and a growing preference for self-injection devices significantly contribute to this rapid growth. The increasing demand for biosimilars and generics, alongside innovations in injection systems, has bolstered the market landscape. Furthermore, demographic factors, particularly an aging population and improvements in healthcare infrastructure, are expected to provide substantial momentum to the market during the forecast period.

Europe holds a significant position in the Injectable Drug Delivery Devices Market, characterized by a strong regulatory environment emphasizing safety and efficacy. The prevalence of chronic diseases in this region is increasing, particularly with breast cancer diagnoses exceeding 530,000 annually, accounting for about 29% of all cancers in women. The area experiences a steady growth rate, supported by advancements in technology that enhance the usability and efficiency of injection devices. A shift towards self-administration and connected injection systems, facilitating better patient adherence, plays a crucial role in this market. Major players are investing in R&D to meet stringent regulatory requirements while addressing the evolving needs of patients across Europe.

Based on the provided market data, Vantage Market Research offers customizations in the reports to meet the specific needs of clients.

Key Trends

1. Growing Preference for Self-Administration: There is a significant shift towards self-injection devices that empower patients to manage their health better.​ Self-injection devices, including auto-injectors and needle-free systems, are gaining popularity due to their convenience and ability to be used at home.
2. Advancements in Device Technology: Innovations are focused on developing user-friendly and customizable devices. Newer models are designed with adjustable speed and depth during injections, which helps minimize discomfort and enhance patient experience.
3. Rise of Connected and Smart Devices: Integrating digital health technologies is becoming commonplace, resulting in the developing of connected injection systems. These devices can monitor dosing schedules and patient adherence, essential for chronic disease management.
4. Emergence of Alternative Drug Delivery Systems: While injectable devices are essential, the market is witnessing significant competition from alternative delivery systems such as nasal and transdermal patches. These alternatives offer painless administration options, affecting patient preferences.
5. Investment in Regulatory Approvals: Companies are experiencing a rise in regulatory compliance requirements, particularly for new large-volume delivery systems. This trend aims to ensure the efficacy and safety of pharmaceutical drug delivery systems for patients.
6. Emphasis on Cost-Effective Solutions: As healthcare costs continue to rise, there is a drive towards creating affordable injectable systems. This trend highlights the need for cost efficiencies in manufacturing and distribution, making medications more accessible to a broader patient demographic.
7. Increased Demand for Long-Acting Formulations: There is a notable trend toward developing long-acting injectable formulations that reduce dosing frequency. This approach improves patient compliance and enhances therapeutic outcomes across various treatment areas.

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

Market Definition

​Injectable drug delivery refers to administering medications directly into the body through injections, allowing for rapid absorption and effective treatment, particularly for biologics and chronic diseases.​ Injectable Drug Delivery Devices include tools such as prefilled syringes, auto-injectors, and pen-injectors, all designed to enhance patient convenience, ensure precise dosing, and improve medication adherence. These advancements streamline treatment, especially for patients requiring long-term management of diabetes and arthritis.

Market Dynamics

Increasing Prevalence of Chronic Diseases Such as Cancer, Autoimmune Disorders, And Renal Diseases Propel Market Expansion

​

High Costs Associated with Apheresis Procedures and The Required Equipment Challenges Limit Market Accessibility

However, the Apheresis Equipment Market faces notable restraints, particularly the high costs associated with apheresis procedures and the required equipment. The sophisticated nature of apheresis technology necessitates substantial initial investments, making it challenging for healthcare facilities in resource-limited settings to adopt such methods. Moreover, the complexities involved in apheresis processes demand specialized training and expertise, which can hinder widespread implementation. Stringent government regulations surrounding the use and reimbursement of apheresis devices further complicate matters, often leading to delays in product availability and market penetration.

Technological Innovations, Such as Automated and Portable Apheresis Devices, Offer Growth Opportunities

The Apheresis Equipment Market presents significant opportunities, particularly in emerging economies with rapidly developing healthcare infrastructure. Countries in the Asia Pacific region, such as China and India, are witnessing an increasing prevalence of chronic diseases, driving demand for advanced medical treatments, including apheresis. There are noteworthy opportunities for growth, particularly in treating leukemia and among pediatric patients. With an estimated 62,770 new instances of leukemia projected in 2024 alone in the U.S., therapeutic apheresis is becoming vital in managing the disease by effectively removing malignant cells. Additionally, innovations in technology, such as automated and portable apheresis devices, enhance the efficiency and usability of these treatments, improving patient access and compliance. There is also a growing focus on developing sophisticated, user-friendly equipment that integrates artificial intelligence and data analytics, enhancing procedural monitoring and management and further catalysing market growth.

Competitive Landscape

The Injectable Drug Delivery Devices Market is characterized by intense competition among prominent players, including Becton, Dickinson and Company, Pfizer Inc., and Eli Lilly and Company, which continuously innovate to enhance their product portfolios. Significant technological advancements, such as the introduction of prefillable syringes and automated delivery systems, have been pivotal in meeting the increasing demand for biologics and self-injection solutions. ​Approximately 45% of the market share is held by the top five companies investing heavily in research and development to gain competitive advantages.​ The ongoing trend of mergers and acquisitions further intensifies competition as companies seek to diversify their offerings and expand their geographical presence to capitalize on the growing demand for injectable drug delivery systems, mainly due to the rising burden of chronic diseases such as obesity, diabetes, and cancer.

Recent Market Developments

Biocon Partners with Handok to Commercialize Synthetic Liraglutide for Chronic Weight Management

• In May 2024, Biocon Limited entered into an exclusive licensing agreement with South Korean specialty pharmaceutical company Handok to commercialize Synthetic Liraglutide, a complex drug product designed for chronic weight management. This medication will be offered as a supplementary treatment in conjunction with a reduced-calorie diet and increased physical activity

Johnson & Johnson Acquires Ambrx Biopharma in a $2.0 Billion All-Cash Deal

• In March 2024, Johnson & Johnson completed its acquisition of Ambrx Biopharma, a clinical-stage biopharmaceutical company with a proprietary synthetic biology platform for next-generation antibody-drug conjugates, through an all-cash merger valued at $2.0 billion, or $1.9 billion net of estimated cash acquired

Aptar Digital Health and SHL Medical Collaborate on Injectable Therapies

• In June 2024, Aptar Digital Health partnered with SHL Medical to enhance patient experiences in injectable therapies. The collaboration integrates Aptar Digital Healths Software as a Medical Device (SaMD) platform with SHL Medicals advanced drug delivery systems, including the Molly Connected Cap for the Molly autoinjector. This initiative aims to provide digital self-administration support tailored to patient profiles, disease states, and treatment plans

West Pharmaceutical and Corning Expand Collaboration

• In February 2023, West Pharmaceutical Services, Inc. and Corning Incorporated expanded their collaboration by launching the West Ready Pack with Corning Valor RTU Vials, using SG EZ-fill technology. This partnership enhances the storage, delivery, and availability of critical injectable drugs, driving innovation in drug packaging and delivery systems

The global Injectable Drug Delivery Devices market can be categorized as Devices, Therapeutic Application, Usage Pattern, Site of Delivery and Region.